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ABSTRACT: Human glucosylcerebrosidase 2 (GBA2) of the CAZy family GH116 is responsible for the breakdown of
glycosphingolipids on the cytoplasmic face of the endoplasmic reticulum and Golgi apparatus. Genetic defects in GBA2 result in
spastic paraplegia and cerebellar ataxia, while cross-talk between GBA2 and GBA1 glucosylceramidases may aﬀect Gaucher
disease. Here, we report the ﬁrst three-dimensional structure for any GH116 enzyme, Thermoanaerobacterium xylanolyticum
TxGH116 β-glucosidase, alone and in complex with diverse ligands. These structures allow identiﬁcation of the glucoside binding
and active site residues, which are shown to be conserved with GBA2. Mutagenic analysis of TxGH116 and structural modeling
of GBA2 provide a detailed structural and functional rationale for pathogenic missense mutations of GBA2.
Human glucosylcerebrosidase 2 (GBA2, nonlysosomalglucosylcerebrosidase, E.C. 3.2.1.45, bile acid β-glucosi-
dase E.C. 3.2.1.21) is a member of a family of sequence-related
glycoside hydrolases (GH) designated GH116 (see www.cazy.
org), with members in animals, plants, fungi, archaea, and
eubacteria.1−3 Originally identiﬁed as a bile acid β-glucosidase,4
GBA2 was later found to hydrolyze the glycolipids glucosylcer-
amide (GlcCer) and glucosyllysosphingosine, and its defect was
found to disrupt glycolipids in sperm and cause infertility in
knockout mice.5
GBA2 is a peripheral membrane protein localized to the
cytoplasmic face of the endoplasmic reticulum and/or Golgi
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apparatus membrane.6 GBA2 and the lysosomal family GH30
glucosylcerebrosidase GBA1 (GBA, acid β-glucosidase) are
thought to be the primary enzymes responsible for the
breakdown of GlcCer.7 GlcCer is the most abundant
glycosylceramide, a common precursor for the majority of
more complex glycosphingolipids, and an important messenger
in its own right.8,9 While there is extensive structural and
functional knowledge of GBA1, genetic deﬁciency of which
results in the lysosomal storage disease Gaucher disea-
se,10,11much less is known of GBA2.
Mutations in the human GBA2 gene cause hereditary spastic
paraplegia (HSP) and autosomal recessive cerebellar ataxia
(ARCA).12−15 Zebraﬁsh with the corresponding gene knockout
also show neurological defects.12 Signiﬁcantly, knockout of
GBA2 in mouse models for Gaucher disease and Niemann-Pick
disease, in which there is a secondary deﬁciency in GBA1,
partially alleviated symptoms.16,17 Furthermore, overexpression
of GBA2 was found to be toxic to melanoma cells.18 Taken
together, this suggests that speciﬁc inhibitors and activators of
GBA2 could be useful for the treatment of Gaucher disease,
hereditary ataxias, and possibly melanoma. Although GBA2
inhibitors have been identiﬁed,7,19,20 the lack of any structural
insight for GBA2, or indeed any other GH116 protein, has
limited both the rational development of more potent
inhibitors and the molecular understanding of pathogenic
mutations.
Glycoside hydrolase family GH116 includes enzymes with
diverse speciﬁcities, including a β-xylosidase/β-glucosidase3 and
an N-acetylglucosaminidase,21 the biochemical analysis of
which has been useful in deﬁning the basic catalytic machinery,
including the general acid/base and catalytic nucleophile.
However, these biochemically characterized members are
divergent from mammalian GBA2 and lack conservation of
residues that have been identiﬁed to be mutated in GBA2-
related disorders. Here, we describe the three-dimensional
structure of a bacterial homologue of the human GBA2, the ﬁrst
3-D structure for this important family of glycosidases, in native
and ligand complexes. Through functional analysis of this
highly tractable model, in which all pathogenic GBA2 mutation
sites are strictly conserved, we provide detailed insight into the
molecular bases of human GBA2 mutations leading to ataxias
and paraplegias.
■ RESULTS AND DISCUSSION
Enzyme Activity and Small Molecule Inhibition. Given
the absence of any 3-D model or structure for the human
enzyme, we sought to work on a close bacterial homologue of
GBA2. Thermoanaerobacterium xylanolyticum GH116
(TxGH116) shares approximately 40% sequence identity over
the catalytic domain, and we predicted it would share glucose-
speciﬁcity and identity in the glucose-binding residues in the
active site. Recombinant TxGH116 is indeed active on 4-
nitrophenyl (4NP) β-D-glucoside (4NPGlc) and other gluco-
sides (Table 1). Michaelis Menten kinetics, determined at 60
°C (the temperature of the Frying Pan Hot Springs, from
which T. xylanolyticum was isolated22), revealed that 4NPGlc is
hydrolyzed 17 times as eﬃciently, in terms of kcat/KM, than the
corresponding β-D-galactoside, 4NPGal. TxGH116 has a pH
optimum of 5.5 and shows high activity toward both β-1,3- and
β-1,4-linked glucooligosaccharides, with similar kcat and KM
values for both cellobiose and laminaribiose (Table 2). Since T.
xylanolyticum was isolated based on its growth on plant cell wall
polysaccharides,22 these oligosaccharides are likely natural
substrates for the enzyme. Although we were unable to detect
hydrolysis of glucosylceramide, TxGH116 does hydrolyze alkyl
glycosides including n-heptyl glucoside and n-octyl glucoside.
With knowledge that the enzyme was a β-glucosidase, and given
its high sequence similarity to GBA2, we were encouraged to
determine the three-dimensional structure of TxGH116, as a
model for family GH116.
Three-Dimensional Structures of TxGH116. TxGH116
crystallized in space groups P21212 and P61, and its structure
was solved and reﬁned at 1.61 Å (Table 3). The absence of
Table 1. Speciﬁc Activity of TxGH116 and Catalytic Residue
Mutants with Aryl and Alkyl Glycosides and
Oligosaccharides
speciﬁc activity (μmol mg−1 min−1)a,b
substrate
TxGH116 wild
type D593A E441A
4NP β-D-glucoside 27.3 (100%) 0.0772 (100%) 0.000528
4NP β-D-galactoside 8.90 (33%) -c -c
4NP N-acetyl-β-D-
glucosaminide
0.123 (0.45%) - -
4NP α-D-galactoside < 0.01
(<0.04%)
- -
4NP α-L-arabinoside < 0.01
(<0.04%)
- -
4NP β-D-fucoside < 0.01
(<0.04%)
- -
4NP α-D-glucoside < 0.01
(<0.04%)
- -
4NP β-D-mannoside < 0.01
(<0.04%)
- -
4NP β-D-xyloside < 0.01
(<0.04%)
- -
4NP β-cellobioside 0.302 (1.1%) - -
gentiobiose 2.23 (8.2%) - -
sophorose 4.10 (15%) - -
laminaribiose 11.7 (43%) 0.000245
(0.32%)
-
laminaritriose 16.1 (59%) 0.000478
(0.62%)
-
laminaritetraose 15.0 (55%) 0.000490
(0.62%)
-
laminaripentaose 16.5 (60%) 0.000524
(0.68%)
-
cellobiose 13.4 (49%) 0.000345
(0.45%)
-
cellotriose 15.6 (57%) 0.000538
(0.70%)
-
cellotetraose 14.9 (55%) 0.000498
(0.65%)
-
cellopentaose 13.8 (51%) 0.000448
(0.58%)
-
cellohexaose 13.5 (49%) 0.000422
(0.55%)
-
methyl β-D-glucoside 0.0817 (0.30%) - -
n-heptyl-β-D-glucoside 3.74 (14%) - -
n-octyl β-D-glucoside 3.58 (13%) - -
aThe assay contained 1 mM substrate in 50 mM MES buﬀer, pH 5.5,
at 60 °C. bPercent activity relative to glucose or 4NP released from
4NP β-D-glucopyranoside is given in parentheses. The values for
disaccharide hydrolysis were determined by dividing the amount of
glucose released by 2, since two glucose molecules are released per
glycosidic bond hydrolyzed. For oligosaccharides, which may release
more than one glucose molecule per substrate molecule due to
sequential cleavage, the values quoted are for total glucose released.
cThe dashes mean that the values were not determined for the mutant
enzymes due to low activity.
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structural homologues necessitated a SeMet-derivatized protein
for structure solution by single wavelength anomalous
dispersion (see Methods). The structure consists of an N-
terminal domain, primarily formed by a two-sheet β-sandwich,
and a C-terminal (α/α)6 solenoid domain, Figure 1A. The C-
terminal domain contains the residues previously proposed as
the catalytic nucleophile and general acid/base in the archaeal
β-glycosidase from Sulfolobus solfataricus and human
GBA2.3,7The putative catalytic nucleophile, E441 (equivalent
to human GBA2 E527), lies near the end of a long loop
between the ﬁrst (H5) and second (H6) α-helices of the C-
terminal domain, while the putative catalytic acid/base, D593
(equivalent to human GBA2 D677), lies in a long loop between
the ﬁfth (H9) and sixth (H10) helices of the solenoid (Figure
1A). This loop also contains the binding site for a structural
Ca2+ ion (Supporting Information, Figure S1A).
GBA2 was previously thought to be an intrinsic membrane
protein with residues 689−708 predicted as a transmembrane
domain but is easily extracted from cells in buﬀer without
detergents.2,6 The previously predicted hypothetical trans-
membrane domain corresponds to H10, an internal helix in the
catalytic domain of TxGH116 and the derived GBA2 model,
which is incompatible with it being a transmembrane helix. Our
model therefore supports the peripheral membrane localization
of GBA2, where it may bind to an intrinsic membrane protein
or polar lipid head groups.
TxGH116 shows no structural similarity to other retaining β-
glucosidases, which fall into families including GH1, GH2,
GH3, GH5, and GH30 (SI, Figure S2). Comparison to
structures in the PDB database with PDBeFold23 found that the
TxGH116 structure is most similar to the family GH52 β-
xylosidase from Geobacillus thermoglucosidasius (GtGH52, PDB
ID: 4C1O, 4C1P),24 which upon global superposition yields an
RMSD of 3.2 Å over 560 matched Cα atoms (PDBeFold Z
score 8.3; SI, Figure S3A). However, the sequence similarity of
GH52 and GH116 is negligible (GH52 enzymes are not
detected using PSI-BLAST with the TxGH116 sequence as a
search query), GH52 lacks the N-terminal loop that contributes
to the entrance to the active site in GH116, and diﬀerent
numbers of strands are found in the major β-sheets of the N-
terminal domain (see SI). Nonetheless, the active sites also
share the same geometry for the putative acid/base and
nucleophile and a few sugar binding residues (SI Figure S3)
allowing us to propose that these two divergent families be
grouped as a “clan” (GH-O) of related 3-D structures.25
Catalytic Residues and Active Site Structure. GH116
family enzymes act via a double-displacement mechanism in
which a covalent glycosyl enzyme intermediate is formed and
subsequently hydrolyzed via oxocarbenium-ion like transition
states (SI Figure S4). Such a mechanism demands two key
residues: a general acid/base and a nucleophile. The putative
acid/base, D593, is located approximately 8 Å (carboxylate to
carboxylate) away from the nucleophile (E441; Figure 1B,C) in
the P21212 structure and 10 Å away in the P61 structure due to
a displacement of the loop containing D593 by 2 Å (not
shown). This is a longer distance than is observed in most
retaining β-glucosidases, which typically have the acid/base
within 4.5−6.5 Å of the nucleophile.26−29 Given this ambiguity,
we veriﬁed that the enzyme is retaining by identifying the initial
hydrolysis product as β-D-glucose, which retains the anomeric
stereochemistry of the substrate, by monitoring the reaction
time course by NMR spectroscopy (SI, Figure S5A). Moreover,
we demonstrated that E441 is the catalytic nucleophile and
D593 the catalytic acid/base by mutation of these residues to
alanine (which resulted in large losses of activity, Table 1),
followed by chemical rescue30 using small nucleophiles (see SI,
Figures S5B−D).
Several established β-glucosidase inhibitors were examined to
identify ligands that could bind in the active site. TxGH116 is
inhibited by the covalent inactivator 2,4-dinitrophenyl 2-deoxy-
2-ﬂuoro-β-D-glucoside (DNP2FG),31 and by the noncovalent
inhibitors isofagomine (IFG), deoxynojirimycin (DNJ),
glucoimidazole (GIM), δ-gluconolactone (weak inhibition at
1 mM), and the product D-glucose (Glc). Inhibition by IFG,
DNJ, GIM, and Glc is competitive with Ki values of 2.9 ± 0.1
nM, 0.13 ± 0.01 μM, 0.34 ± 0.03 μM, and 4.0 ± 0.3 mM,
respectively (SI Figure S6). TxGH116 was not inhibited by
conduritol B epoxide (CBE), an inhibitor that has been used to
distinguish GBA1 (sensitive) from GBA2 (less sensitive20). In
contrast, cyclophellitol, a related epoxide that contains a
hydroxymethyl group corresponding to the hydroxymethyl
group of glucose, rapidly inactivated TxGH116. The similarity
of the inhibition proﬁle of human GBA2 and TxGH116 with
sugar-shaped inhibitors shows that TxGH116 may be
considered an informative functional model for the glycone-
binding (−1) subsite of the human enzyme.
Table 2. Kinetic Parameters of TxGH116 and Its Mutants for Hydrolysis of 4NP-Glycosides and Oligosaccharides
kinetic parameters (60 °C) temperature
protein substrate KM (mM) kcat (s
−1) kcat/KM (mM
−1 s−1) optimum Tm
WT without N-term taga 4NP β-D-glucoside 0.18 ± 0.008 49.0 ± 0.8 272 75 °C -
4NP β-D-galactoside 16.3 ± 0.94 255 ± 5 15.6
cellobiose 0.25 ± 0.016 44.4 ± 0.7 178
laminaribiose 0.27 ± 0.018 41.4 ± 0.7 153
WT with N-term tagb 4NP β-D-glucoside 0.21 ± 0.012 37.6 ± 0.6 179 75 °C 81.3 °C
D508H 4NP β-D-glucoside 110 ± 3 3.47 ± 0.17 0.031 65 °C 66.5 °C
D508N 4NP β-D-glucoside 41.0 ± 2.5 30.2 ± 0.71 0.74 60 °C 67.2 °C
R544W 4NP β-D-glucoside 0.26 ± 0.011 48.2 ± 0.53 186 60 °C 76.2 °C
R786H 4NP β-D-glucoside 15.7 ± 0.50 193 ± 2.4 12.3 70 °C 73.9 °C
aWild type without the N-terminal tag is used for comparison to R544W and R786H, which were puriﬁed in the same way as the crystallized protein.
bWild type with the N-terminal tag is used for comparison to D508H and D508N, which could not be digested with enterokinase without internal
cleavage of the protein. Temperature optimum curves are shown in SI Figure S8A. Melting temperatures (Tm) for all mutant proteins are those for
the fusion protein without removal of the N-terminal tag. All Tm values were determined based on the change in circular dichroism at 220 nm upon
heating. The melting curves are provided in SI Figure S8B.
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Insight into the active site and catalytic residues was obtained
by solving the structures of TxGH116 in complexes with a
trapped intermediate derived from DNP2FG, the inhibitors
DNJ and GIM, and the product (Glc) (Figure 2). The 2-
ﬂuoroglucosyl moiety binds to the catalytic nucleophile E441,
consistent with the equivalent residue labeled by DNP2FG in
studies with Sulfolobus solfataricus (E335) and human enzymes
(E527),3,7 and the mutagenesis and chemical rescue studies
described in the SI. The putative acid/base, D593, is located in
an unorthodox position above the pyranose ring, rather than in
a typical position in the plane of the sugar ring which provides
for syn- or anti- lateral protonation of the glycosidic oxygen.32
Its position above the plane of the sugar ring prevents the
eﬃcient lateral protonation of GIM that is required for its
strong binding, thus explaining the weak inhibition by this
molecule.32
The structure of the glycosyl enzyme (Figure 2A) enabled
identiﬁcation of residues interacting with the substrate in the
−1 subsite. The amino acid residues capable of forming
hydrogen bonding interactions include E441 at OH2 (F2 in
G2F); H507 and D452 at OH3; D452, T591, and R792 at
OH4; and E777 and R786 at the OH6. In the last case, OH6
appears to mediate a salt bridge between E777 and R786. The
interactions at OH6 may explain why cyclophellitol, bearing a
hydroxymethyl group equivalent to the substrate C6-hydroxy-
methyl group, inhibits TxGH116, but CBE, which lacks this
group, does not. All of the glucosyl binding residues in
TxGH116 are conserved with human GBA2, whereas only a
few of these could be reliably aligned with a conserved residue
in the two biochemically characterized archaeal enzymes,
SSO1353 and SSO3039 (SI Figure S7).
The complexes with DNJ and GIM and the product Glc
reveal similar interactions to those seen in the G2F
intermediate (Figure 2B−D). In the complexes with Glc and
DNJ, the pyranose/piperidine rings are in 4C1 chairs, while
GIM adopts a 4H3 conformation, corresponding to the
preferred low energy conformations of these ligands.33
Model of Human GBA2 and Context of Disease-
Causing Mutations. Human GBA2 and TxGH116 share 37%
sequence identity over the region of GBA2 residues 63 to 893,
allowing an informative homology model of GBA2 to be
generated from TxGH116. Two longer loops in GBA2, one of
which may contribute to the aglycone-binding cleft leading into
the active site, as does the corresponding loop in TxGH116
Figure 1. Three-dimensional structure of TxGH116 β-glucosidase. (A) Three views of the three-dimensional structure of TxGH116. The N-terminal
domain consists of β-sheets (sheets 1−3) surrounded by α-helices (H1−H4). The C-terminal (α/α)6 solenoid domain contains the active site and
consists of 12 α-helices (H5−H16) in six outer helix plus inner helix pairs, with H5 situated between the two domains. A long loop with a two-strand
β-sheet (sheet 5) lies between helices H7 and H8, near the active site (E441 and D593). α-Helices are shown in blue and β-strands in yellow. (B)
Active site residues of the native structure of TxGH116, showing the distance between the catalytic nucleophile (E441) and acid/base (D593)
carbons (red labels). (C) Active site of the TxGH116 covalent intermediate complex with 2-deoxy-2-ﬂuoroglucose, showing the distance between
the catalytic residues is decreased in this intermediate. Distances between the geometric means of the carboxyl groups are slightly shorter and are
given in the text. Distances are in Å.
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(Figure 3A), could not be modeled with high conﬁdence.
Notably, there is excellent correspondence between the active
site residues, with all the residues noted as binding the sugar in
TxGH116 conserved in human GBA2 (Figure 3C).
Known pathogenic human GBA2 mutations include ﬁve
missense mutations, F419V, D594H, R630W, G683R, and
R873H (Figure 3B).12−15,34 The amino acid residues
corresponding to the sites of these mutations are conserved
between GBA2 and TxGH116 (F347, D508, R544, G599, and
R786, respectively), as well as other GH116 enzymes in
subfamily 1, which includes eukaryotic and bacterial enzymes
(SI Figure S7).21 As shown in Figure 3C, the GBA2 D594 and
R873 residues (TxGH116: D508 and R786) are located within
the active site, providing an immediate catalytic implication for
these mutations. As noted earlier, TxGH116 R786 makes two
hydrogen bonds to the glucosyl 6OH group, which are
predicted to be conserved in GBA2 R873. The mutation
R873H will result in a shorter side chain, which will not form
an eﬀective hydrogen bond to O6 of Glc. In TxGH116, D508
hydrogen bonds to H507, which in turn makes a hydrogen
bond to OH3, and the D594 residue makes the same
interaction with the conserved H593 in the GBA2 model.
The mutation D594H is expected to disrupt this interaction.
The fact that two human pathogenic mutations involve sugar-
binding residues emphasizes the importance of this model.
In contrast to the D584H and R873H, the other three
missense mutations are located distal to the active site. The
R630W mutation is approximately 15 Å away from the active
site, between the layers of helices of the catalytic (α/α)6
solenoid domain. The GBA2 model shows that R630 can
form salt bridge interactions with two conserved carboxylates,
E555 and D631 (Figure 3D). The mutation R630W will result
in the loss of a charged residue, disturbing the charge balance,
and introduction of a somewhat larger Trp residue, which
together may result in destabilization of the protein. The only
pathogenic mutation found in the N-terminal β-sandwich
domain is F419V. F419 is positioned at the interface of the two
domains, and the aromatic ring appears to form dispersive
interactions with the conserved neighboring aromatic residues
Y534 in the long loop between the H5 and H6 helices and
W603 in the loop between the H7 and H8 helices of the C-
terminal (α/α)6 solenoid domain (Figure 3B,E). V419 cannot
make such interactions, so the F419V mutation may destabilize
the interaction between the two domains. The G683R
mutation, located approximately 20 Å from the active site, is
in an outside turn of the long loop including the catalytic acid/
base (D677) and the sugar-binding residue T675 (Figure 3F).
G683 is located very close to the neighboring loop, in which
S741 is closest to G683, such that a replacement with arginine
would result in a clash. It is also next to the binding site for the
calcium cation in TxGH116, suggesting that a positively
charged Arg could disrupt this binding.
It was recently shown that expression of GBA genes
possessing all known pathogenic mutations in COS-7 or
HeLa cells resulted in reduced activity in crude cell extracts
relative to wild-type.34 We sought to gain insight into the
physical and mechanistic eﬀects of the pathogenic GBA2
D594H, R630W, and R873H mutations by analysis of
corresponding mutations in TxGH116. For all three mutations,
TxGH116 D508H, R544W, and R786H (corresponding to
GBA2 D594H, R630W, and R873H), large decreases in activity
were observed at the temperature optimum of the wild type
enzyme (Table 2, SI Figure S8). For the TxGH116 R786H
mutation (corresponding to GBA2 R873H), a 90-fold increase
in the KM value led to a reduction in kcat/KM of more than 20-
fold (Table 2), which is consistent with the weaker binding of
the sugar expected based on this residue’s interaction with the
Figure 2. Active site of TxGH116 alone and in complex with
inhibitors and glucose. Left panels show the ligand electron density
omit maps, contoured at 3σ, in the active sites of the complexes; the
right panels show the potential hydrogen bonds between the ligands
and surrounding residues, with the distances between the interacting
atoms displayed. A glycerol molecule that was omitted from the left
panels for clarity is shown in the right panels; catalytic residues are
labeled in red. Ligands include (A) 2-deoxy-2-ﬂuoroglucosyl (G2F),
(B) deoxynojirimycin (DNJ), (C) glucoimidazole (GIM), and (D) β-
D-glucose. Distances are in Å.
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glucose 6OH. Recapitulation of the GBA2 D594H mutation in
TxGH116 D508H resulted in both decreased stability and
lowered activity (Table 2). Most notably, the kcat/KM value
decreased 5800-fold, owing mostly to a >500-fold increase in
the KM value, with a small reduction in the kcat value. The large
decrease in kcat/KM and relatively small eﬀect on kcat suggests a
large eﬀect on the binding and stabilization of the substrate and
transition state of the ﬁrst committed step of hydrolysis
(glycosylation), whereas the rate limiting step is less aﬀected.
The wild type kcat values for 4NPGlc (possessing a leaving
group with a relatively low pKa value and thus a relatively low
energy barrier for departure) and cellobiose (possessing a poor
glucosyl leaving group with a high pKa value) are similar (Table
2), suggesting that the deglycosylation step (for which the
reaction is the same) is rate-limiting. The small change in kcat in
the D508H mutant suggests that this is most likely also true for
this mutant.35 To investigate the importance for catalysis of the
charge of D508, the isosteric mutation D508N, which should
maintain hydrogen bonding to H507, was studied. D508N
exhibited a >240-fold reduction in kcat/KM, and thus, the
negative charge on D508 appears to be important for catalysis.
The eﬀect of the GBA2 R630W mutation was studied
through the TxGH116 R544W mutant. The R544W mutant
exhibited a slightly increased KM value and little change in the
melting temperature but caused a decrease in the temperature
of the optimum catalytic activity by 15 °C. These properties
suggest the R544W mutation may destabilize the active site,
while having little eﬀect on the overall protein stability. This
hypothesis is consistent with the observation that a large
amount of GBA2 protein accumulated in COS-7 and HeLa
cells that expressed the R630W variant, suggesting it is not an
unstable protein despite the low level of activity in the standard
GBA assay.34
■ CONCLUSIONS
GBA2 has risen to prominence due to its involvement in
congenital neurological disorders leading to cerebellar ataxia
and spastic paraplegia, as well as its interplay with GBA1,
defects in which cause Gaucher disease and contribute to
Parkinsonism.36 Modulators of GBA2 activity may therefore
provide therapeutic beneﬁts in the treatment of diseases
involving defects in GBA1 or GBA2. The TxGH116 structure
Figure 3. Human GBA2 structural model. (A) Overall structure of the human GBA2 model (purple) superimposed with the TxGH116 structure
(green). The loop adjacent to the active site, which is longer in GBA2, is marked with a red arrow, while the longer loop between helices H5 and H6
of the (α/α)6 solenoid domain is marked with a black arrow. (B) Diagram of human GBA2 model showing positions of residues mutated in human
disease (space-ﬁlling) and interacting residues and ligand (sticks). (C) Superposition of active site residues of human GBA2 and the TxGH116
complex with glucose. All of the sugar binding residues are conserved between TxGH116 and GBA2, as well as the aspartate (D508) that interacts
with H507 in TxGH116. The H-bonds between residues involved in human autosomal recessive cerebellar ataxia mutations and the sugar residue are
shown as dashed lines. The catalytic nucleophile and acid/base labels are underlined. (D) Superposition of human GBA2 model (purple) on
TxGH116 structure (green) in the area of the R630 residue mutated in certain hereditary spastic paraplegia cases. R630 and the nearby carboxylate
residues D631 and E555 are conserved with TxGH116 residues. (E) View of GBA2 F419 and the conserved interacting aromatic groups in the
overlay of the GBA2 and TxGH116 models. (F) Position of the GBA2 G683R mutation, showing that, although it is near the surface of the protein,
G683 is tightly opposed to S741 (both shown in magenta spheres) and the bound calcium cation (green sphere) and is also linked to the catalytic
acid/base D677 shown next to the glucosyl residue (cyan carbon sticks).
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described here possesses many unique features, particularly in
the N-terminal β-sandwich, which is tightly associated with the
catalytic domain and contributes to the substrate-binding cleft,
and the unusual orientation of the general acid/base residue.
The residues binding the glucose in the −1 subsite are highly
conserved between TxGH116 and human GBA2, and the
structural model provides a useful framework for understanding
the molecular basis for binding of ligands to the glycone-
binding site. Signiﬁcantly, key missense mutations causing
defects in GBA2 are conserved between the two enzymes,
which have allowed identiﬁcation of likely biochemical and
structural reasons underpinning the genetic defects. The
present work demonstrates that the missense mutations are
located both proximal to and remote from the active site and
result in a loss of enzymatic activity by a range of mechanisms
including reduction in substrate binding, reduced temperature
for optimal catalysis, and reduced enzyme stability.
■ METHODS
Plasmid Construction and Protein Expression. Two inde-
pendent constructs presenting E. coli-optimized TxGH116 genes were
prepared in pET28a(+) and pET30a(+) expression vectors with
polyhistidine tags, as described in the Supporting Information (SI).
The pET28a(+) construct generated a TxGH116 protein with the ﬁrst
20 amino acid residues replaced with an N-terminal His6-tag that was
designated TxGH116-N. The pET30a(+) construct encoded the
TxGH116 protein lacking the ﬁrst 18 amino acids following the
pET30(+) N-terminal tag including a His6 tag, S-tag, and enterokinase
site. This fusion protein, designated TxGH116Δ1−18, also included
the C-terminal His6 tag from the plasmid. The fusion proteins were
produced in E. coli strain BL21(DE3) and puriﬁed by immobilized
metal aﬃnity chromatography, as described in the SI Methods.
Production of selenomethionine-labeled TxGH116 (SeTxGH116) was
accomplished with the pET30a/TxGH116Δ1−18 plasmid in E. coli
strain B834(DE3) pLysS cells grown in a SeMet core medium (Nihon
Jyunyaku Co.; SI Methods).
Enzymatic Characterization. The TxGH116Δ1−18 protein was
used for enzymatic characterization. The optimum pH of TxGH116
for hydrolysis of 4NPGlc was determined to be pH 5.5 by incubating
0.05 μg of enzyme with 1 mM 4NPGlc in 100 mM McIlvaine universal
(phosphate-citrate) buﬀer, pH 2.5−8.0 at 0.5 pH unit intervals, at 60
°C for 30 min. The temperature optimum (75 °C) was determined via
the hydrolysis of 1 mM 4NPGlc with 0.05 μg of enzyme in 50 mM
sodium acetate buﬀer, pH 5.5, at temperatures of 10−110 °C, for 10
min (SI Figure S8A). For standard activity assays, 1 mM 4NPGlc was
incubated with enzyme at 60 °C for 15 min. Chemical rescue activity
of E441A and D593A mutants and wild type TxGH116 were assayed
under conditions of 50 mM MES, pH 5.5, and 60 °C with 1 mM
4NPGlc, 0.1 μg of wild type for 15 min, 25 μg of E441 for 60 min, and
5 μg for 15 min of D593A with sodium formate and sodium azide
concentrations of 0−4 M.
Inhibition constants were determined by assaying triplicate
reactions at ﬁve 4NPGlc substrate concentrations bracketing the
apparent KM value and ﬁve inhibitor concentrations. The inhibitors
were preincubated with 0.05 μg of enzyme at 37 °C for 10 min before
the addition of 4NPGlc and incubation at 60 °C for 15 min. The Ki
values were calculated from the x intercept of the derivative plot of the
slopes of Lineweaver−Burk reciprocal plots (1/v vs 1/[4NPGlc]) vs
the inhibitor concentration (SI Figure S6). Inhibition was competitive
in all cases.
NMR Determination of Retaining Mechanism and Catalytic
Rescue Products. The proton and STD NMR experiments were
performed on a 500 MHz NMR spectrometer (Bruker AVANCE III
HD) with a CPP BBO 500 Cyroprobe and BRUKER TOPSPIN 3.2
software. The 1H NMR spectra were collected at a frequency of
500.366 MHz. The spectra of the 4NPGlc (7.3 mM) hydrolysis
reactions were collected before and 10 and 30 min after adding 50 μM
TxGH116Δ1−18 enzyme.
Mutagenesis. Site-directed mutagenesis was done by the
QuikChange method (Stratagene, Agilent Corp.) to make a catalytic
nucleophile (E441A) and acid/base (D593A) mutations and replicate
pathogenic human GBA2 mutations (D508H and its variant D508N,
R544W, and R786H) in the pET30a/TxGH116Δ1−18 expression
vector. Mutagenic primers are listed in SI Table S1. The mutations and
entire coding sequence were veriﬁed by DNA sequencing (Macrogen).
Protein Crystallization. Crystals were obtained after screening
and optimization by hanging drop vapor diﬀusion at 15 °C in a
precipitant of 0.2 M ammonium sulfate, 20% PEG 3000, 0.1 M MES,
pH 5.5, for TxGH116Δ1−18, and at 19 °C in 0.2 M ammonium
sulfate, 15% w/v PEG 6000, 0.1 M Bis-Tris propane, pH 8, for
TxGH116N.
X-ray Diﬀraction and Structure Solution. Crystals of
TxGH116Δ1−18 were soaked brieﬂy in precipitant containing 20%
glycerol. For ligand complexes, the soaking solution also contained
either 10 mM DNJ, GIM, 2,4-dinitrophenyl 2-deoxy-2-ﬂuoro-β-D-
glucopyranoside (DNPG2F), or 100 mM D-glucose. The crystals were
ﬂash vitriﬁed in liquid nitrogen and data collected at 100 K. Diﬀraction
data were collected at the SPring-8 synchrotron beamline BL44XL
with 0.9000 Å X-ray radiation for native and 0.97865 Å for SeMet
TxGH116Δ1−18 crystals on a MX-300HE detector (Rayonix). The
data were processed with the HKL2000 suite.37 The initial phases were
calculated by the single wavelength anomalous dispersion (SAD)
method with PHENIX AUTOSOL.38 The SAD calculation revealed
one protein molecule per asymmetric unit in the P21212 space group.
The Matthews coeﬃcient was 2.20 Å3/Da, and the solvent content was
44.19%. The SeMet-derivatized protein included 26 SeMet, 25 of
which were observed in the anomalous diﬀerence Fourier map. X-ray
data for TxGH116-N were collected at beamline i24 (wavelength: 0.97
Å) of the Diamond Light Source (Oxfordshire, UK) with a Pilatus3 6
M (100 Hz max. frame rate) detector and processed using MOSFLM
and scaled in SCALA39 to show two protein molecules per asymmetric
unit in the P61 space group. The solvent content was 56%, and the
Matthews coeﬃcient was 2.8 Å3/Da.
The initial phases were transformed to native structure by molecular
replacement with the MOLREP program40 in the CCP4 suite.39 The
structure was built with the COOT graphic program41 in alternation
with reﬁnement with REFMAC5.42 The complex and TxGH116-N
structures were solved by MOLREP40 and reﬁned in a similar manner.
The ﬁnal models were analyzed with PROCHECK43 and MolPro-
bity44 and validated on the PDB Web site. Data and structure
reﬁnement statistics are shown in Table 3.
Molecular Modeling. To construct a homology model of the
human GBA2 protein, the ﬁrst 64 and last 34 residues of the human
protein, which do not have corresponding sequences in TxGH116,
were deleted and the remaining sequence aligned to the TxGH116
sequence and used to build ﬁve models within the Modeler program.45
After the addition of hydrogen and optimization of hydrogen-bonding
side chain rotamers with Molprobity,44 the model with the lowest
Molprobity (3.31) and Clash (108.73) scores was used as the human
GBA2 model. Comparison of the homology model of human GBA2
with the TxGH116 template structure gave an RMSD of 0.543 Å over
712 Cα atoms that could be aligned.
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